Wereldwijd schandaal in de maak: tientallen miljarden stukjes DNA in IEDERE dosis

Steeds meer wetenschappers tonen aan dat de coronavaccins van Pfizer vervuild zijn met DNA-deeltjes, schrijft De Andere Krant.

De Amerikaanse wetenschapper Kevin McKernan bracht afgelopen april een schok teweeg toen hij concludeerde dat de mRNA-vaccins meer DNA-deeltjes bevatten dan de regelgevende instanties toestaan.

Intussen hebben drie andere onderzoekers onafhankelijk van elkaar ontelbare DNA-deeltjes gevonden in Pfizer-vaccins: Sin Hang Lee, de Duitse professor Brigitte König en de Amerikaanse professor Philip Buckhaults.

Problemen alleen maar groter

Laatstgenoemde wilde het in eerste instantie niet geloven, maar tot zijn schrik vond ook hij ontelbare DNA-deeltjes in twee batches Pfizer-vaccins die hij bij een apotheker haalde.

Buckhaults zei dat Pfizer het DNA in kleine stukjes had gehakt, in de hoop dat ze zouden verdwijnen. De farmareus maakte de problemen alleen maar groter, omdat hierdoor het risico op integratie in het menselijk genoom toeneemt.

Volgens hem kunnen de DNA-deeltjes bijdragen aan hartstilstanden, auto-immuunproblemen en kanker.

Wat zou er in vredesnaam verkeerd kunnen gaan?

Het onderzoek van McKernan is beschikbaar als officiële pre-print. Nu nog een tijdschrift zien te vinden dat het lef heeft om het te publiceren, merkt neuroloog Jan Bonte op. Waarop arts David Van Deinse zegt: “Mag niet gepubliceerd worden. De commissie nepnieuws bestaande uit onkundigen zal dit desinformatie noemen.”

In elke dosis van de mRNA-vaccins van Pfizer en Moderna blijken miljarden tot tientallen miljarden stukjes DNA te zitten.

“Nu alleen nog aantonen dat deze stukjes inderdaad geïntegreerd worden in het DNA,” aldus Bonte. “Als ik nu aan alle brulvaxxers denk, kan ik een cynisch glimlachje niet onderdrukken. Voor die mensen geldt: geen leuker vermaak dan leedvermaak. Wat zou er in vredesnaam verkeerd kunnen gaan?”

https://www.ninefornews.nl/wereldwijd-schandaal-in-de-maak-tientallen-miljarden-stukjes-dna-in-iedere-dosis/ 

DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events.

WEB SITE article: https://osf.io/mjc97/

PDF DOWNLOAD :  https://osf.io/mjc97/download

 

AUTHORS

·         David J Speicher

·         Jessica Rose

·         L. Maria Gutschi

·         David M Wiseman PhD

·         Kevin McKernan

Abstract

Background: In vitro transcription (IVT) reactions used to generate nucleoside modified RNA (modRNA) for SARS-CoV-2 vaccines currently rely on an RNA polymerase transcribing from a DNA template. Production of modRNA used in the original Pfizer randomized clinical trial (RCT) utilized a PCR-generated DNA template (Process 1). To generate billions of vaccine doses, this DNA was cloned into a bacterial plasmid vector for amplification in Escherichia coli before linearization (Process 2), expanding the size and complexity of potential residual DNA and introducing sequences not present in the Process 1 template. It appears that Moderna used a similar plasmid-based process for both clinical trial and post-trial use vaccines. Recently, DNA sequencing studies have revealed this plasmid DNA at significant levels in both Pfizer-BioNTech and Moderna modRNA vaccines. These studies surveyed a limited number of lots and questions remain regarding the variance in residual DNA observed internationally.

Methods: Using previously published primer and probe sequences, quantitative polymerase chain reaction (qPCR) and Qubit® fluorometry was performed on an additional 27 mRNA vials obtained in Canada and drawn from 12 unique lots (5 lots of Moderna child/adult monovalent, 1 lot of Moderna adult bivalent BA.4/5, 1 lot of Moderna child/adult bivalent BA.1, 1 lot of Moderna XBB.1.5 monovalent, 3 lots of Pfizer adult monovalent, and 1 lot of Pfizer adult bivalent BA.4/5). The Vaccine Adverse Events Reporting System (VAERS) database was queried for the number and categorization of adverse events (AEs) reported for each of the lots tested. The content of one previously studied vial of Pfizer COVID-19 vaccine was examined by Oxford Nanopore sequencing to determine the size distribution of DNA fragments. This sample was also used to determine if the residual DNA is packaged in the lipid nanoparticles (LNPs) and thus resistant to DNaseI or if the DNA resides outside of the LNP and is DNaseI labile. 

Results: Quantification cycle (Cq) values (1:10 dilution) for the plasmid origin of replication (ori) and spike sequences ranged from 18.44 - 24.87 and 18.03 - 23.83 and for Pfizer, and 22.52 – 24.53 and 25.24 – 30.10 for Moderna, respectively. These values correspond to 0.28 – 4.27 ng/dose and 0.22 - 2.43 ng/dose (Pfizer), and 0.01 -0.34 ng/dose and 0.25 – 0.78 ng/dose (Moderna), for ori and spike respectively measured by qPCR, and 1,896 – 3,720 ng/dose and 3,270 – 5,100 ng/dose measured by Qubit® fluorometry for Pfizer and Moderna, respectfully. The SV40 promoter-enhancer-ori was only detected in Pfizer vials with Cq scores ranging from 16.64 – 22.59. In an exploratory analysis, we found preliminary evidence of a dose response relationship of the amount of DNA per dose and the frequency of serious adverse events (SAEs). This relationship was different for the Pfizer and Moderna products. Size distribution analysis found mean and maximum DNA fragment lengths of 214 base pairs (bp) and 3.5 kb, respectively. The plasmid DNA is likely inside the LNPs and is protected from nucleases.

Conclusion: These data demonstrate the presence of billions to hundreds of billions of DNA molecules per dose in these vaccines. Using fluorometry, all vaccines exceed the guidelines for residual DNA set by FDA and WHO of 10 ng/dose by 188 – 509-fold. However, qPCR residual DNA content in all vaccines were below these guidelines emphasizing the importance of methodological clarity and consistency when interpreting quantitative guidelines. The preliminary evidence of a dose-response effect of residual DNA measured with qPCR and SAEs warrant confirmation and further investigation. Our findings extend existing concerns about vaccine safety and call into question the relevance of guidelines conceived before the introduction of efficient transfection using LNPs. With several obvious limitations, we urge that our work is replicated under forensic conditions and that guidelines be revised to account for highly efficient DNA transfection and cumulative dosing.